This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): ANA598, RG7790, RO5466731
Description: ANA598 is a potent and selective non-nucleoside inhibitor of HCV genotypes 1a and 1b NS5b RNA polymerases and of HCV replication in cell culture.
Deal Structure: In October 2011, Anadys announced that it has entered into a definitive merger agreement to be acquired by Roche. Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share. This corresponds to a total cash consideration of approximately USD 230 million. In November 2011, the acquisition was completed.
Additional information available to subscribers only: